Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19235627 | 0.79 | ACHE (0.37) | ACHE | |
| SCHEMBL18849453 | 0.78 | ACHE (0.35) | KDM4EEPHX1EPHX2ACHECHRM5 | |
| SCHEMBL9906605 | 0.74 | CYP2A13 (0.41) | KDM4EACHECHRM5ADRA2CALDH1A1 | |
| SCHEMBL988572 | 0.74 | CHRM5 (0.48) | ACHECHRM5ADRA2C | |
| SCHEMBL7853978 | 0.73 | KDM4E (0.50) | KDM4EEPHX1EPHX2BPTFHSD11B1 | |
| SCHEMBL13209581 | 0.73 | CHRM5 (0.35) | KDM4EACHECHRM5ADRA2CLMNA | |
| SCHEMBL9906606 | 0.73 | CHRM5 (0.60) | ACHECHRM5ADRA2C | |
| Hydrochloric Acid SCHEMBL11558196 | 0.72 | CHRM5 (0.46) | KDM4EACHECHRM5ADRA2C | |
| SCHEMBL6313781 | 0.72 | KDM4E (0.56) | KDM4EEPHX2BPTFHSD11B1CYP11B1 | |
| SCHEMBL18392104 | 0.70 | NCF1 (0.45) | ACHECHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161655-B2 | Methods of treating mycobacterial infections using tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-20250332178-A1 | METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12161655-B2 | Methods of treating mycobacterial infections using tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024225334-A1 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING PROGRAM, AND INFORMATION PROCESSING METHOD | 株式会社MEMORY LAB | 2024-10-31 | — | — | WO | disclosed |
| US-12088930-B2 | Information processing system, information processing method, and memory medium | Safie Inc. (JP) | 2024-09-10 | — | — | US | disclosed |
| US-20240187743-A1 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND MEMORY MEDIUM | Safie Inc. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | KDM4E 2686/4885EPHX1 925/4885EPHX2 839/4885 |
| US-20250332178-A1 | METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDS | TREH, TBCA, OTC | KDM4E 3007/4885EPHX1 3327/4885EPHX2 4138/4885 |
| US-12161655-B2 | Methods of treating mycobacterial infections using tetracycline compounds | TREH, TBCA, OTC | KDM4E 3007/4885EPHX1 3327/4885EPHX2 4138/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | KDM4E 716/4885EPHX1 222/4885EPHX2 337/4885 |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | KDM4E 2466/4885EPHX1 2441/4885EPHX2 3003/4885 |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | KDM4E 2466/4885EPHX1 2441/4885EPHX2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.